Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Older adults: panoramic view on the COVID-19 vaccination

  • Received: 06 February 2021 Accepted: 06 May 2021 Published: 08 May 2021
  • In December 2020, COVID-19 vaccination started in many countries, with which the world community hopes to stop the further spread of the current pandemic. More than 90% of sick and deceased patients belong to the category of older adults (65 years and older). This category of the population is most vulnerable to infectious diseases, so vaccination is the most effective preventive strategy, the need for which for older adults is indisputable. Here we briefly summarize information about age-related changes in the immune system and present current data on their impact on the formation of the immune response to vaccination. Older age is accompanied by the process of biological aging accompanied by involution of the immune system with increased susceptibility to infections and a decrease in the effect of immunization. Therefore, in the ongoing mass COVID-19 vaccination, the older adults are a growing public health concern. The authors provide an overview of the various types of COVID-19 vaccines approved for mass immunization of the population by the end of 2020, including older adults, as well as an overview of strategies and platforms to improve the effectiveness of vaccination of this population. In the final part, the authors propose for discussion a system for assessing the safety and monitoring the effectiveness of COVID-19 vaccines for the older adults.

    Citation: Boris G Andryukov, Natalya N Besednova. Older adults: panoramic view on the COVID-19 vaccination[J]. AIMS Public Health, 2021, 8(3): 388-415. doi: 10.3934/publichealth.2021030

    Related Papers:

    [1] Abdulqadir J. Nashwan, Rejo G. Mathew, Reni Anil, Nabeel F. Allobaney, Sindhumole Krishnan Nair, Ahmed S. Mohamed, Ahmad A. Abujaber, Abbas Balouchi, Evangelos C. Fradelos . The safety, health, and well-being of healthcare workers during COVID-19: A scoping review. AIMS Public Health, 2023, 10(3): 593-609. doi: 10.3934/publichealth.2023042
    [2] Val Bellman, David Thai, Anisha Chinthalapally, Nina Russell, Shazia Saleem . Inpatient violence in a psychiatric hospital in the middle of the pandemic: clinical and community health aspects. AIMS Public Health, 2022, 9(2): 342-356. doi: 10.3934/publichealth.2022024
    [3] Thiresia Sikioti, Afroditi Zartaloudi, Despoina Pappa, Polyxeni Mangoulia, Evangelos C. Fradelos, Freideriki Eleni Kourti, Ioannis Koutelekos, Evangelos Dousis, Nikoletta Margari, Areti Stavropoulou, Eleni Evangelou, Chrysoula Dafogianni . Stress and burnout among Greek critical care nurses during the COVID-19 pandemic. AIMS Public Health, 2023, 10(4): 755-774. doi: 10.3934/publichealth.2023051
    [4] Katherine Karacaoglu, Calum F Leask . Staff views of a hospital at home model implemented in a Scottish care setting. AIMS Public Health, 2021, 8(3): 467-478. doi: 10.3934/publichealth.2021036
    [5] Elham Hatef, Zachary Predmore, Elyse C. Lasser, Hadi Kharrazi, Karin Nelson, Idamay Curtis, Stephan Fihn, Jonathan P. Weiner . Integrating social and behavioral determinants of health into patient care and population health at Veterans Health Administration: a conceptual framework and an assessment of available individual and population level data sources and evidence-based measurements. AIMS Public Health, 2019, 6(3): 209-224. doi: 10.3934/publichealth.2019.3.209
    [6] Sukhbir Singh, Manjunath B Govindagoudar, Dhruva Chaudhry, Pawan Kumar Singh, Madan Gopal Vashist . Assessment of knowledge of COVID-19 among health care workers-a questionnaire-based cross-sectional study in a tertiary care hospital of India. AIMS Public Health, 2021, 8(4): 614-623. doi: 10.3934/publichealth.2021049
    [7] Muhammad Mutasim Billah Tufail, Muhammad Shakeel, Faheem Sheikh, Nuzhat Anjum . Implementation of lean Six-Sigma project in enhancing health care service quality during COVID-19 pandemic. AIMS Public Health, 2021, 8(4): 704-719. doi: 10.3934/publichealth.2021056
    [8] Vasiliki Georgousopoulou, Panagiota Pervanidou, Pantelis Perdikaris, Efrosyni Vlachioti, Vaia Zagana, Georgios Kourtis, Ioanna Pavlopoulou, Vasiliki Matziou . Covid-19 pandemic? Mental health implications among nurses and Proposed interventions. AIMS Public Health, 2024, 11(1): 273-293. doi: 10.3934/publichealth.2024014
    [9] Christos Sikaras, Ioannis Ilias, Athanasios Tselebis, Argyro Pachi, Sofia Zyga, Maria Tsironi, Andrea Paola Rojas Gil, Aspasia Panagiotou . Nursing staff fatigue and burnout during the COVID-19 pandemic in Greece. AIMS Public Health, 2022, 9(1): 94-105. doi: 10.3934/publichealth.2022008
    [10] Calum F Leask, Andrea Gilmartin . Implementation of a neighbourhood care model in a Scottish integrated context—views from patients. AIMS Public Health, 2019, 6(2): 143-153. doi: 10.3934/publichealth.2019.2.143
  • In December 2020, COVID-19 vaccination started in many countries, with which the world community hopes to stop the further spread of the current pandemic. More than 90% of sick and deceased patients belong to the category of older adults (65 years and older). This category of the population is most vulnerable to infectious diseases, so vaccination is the most effective preventive strategy, the need for which for older adults is indisputable. Here we briefly summarize information about age-related changes in the immune system and present current data on their impact on the formation of the immune response to vaccination. Older age is accompanied by the process of biological aging accompanied by involution of the immune system with increased susceptibility to infections and a decrease in the effect of immunization. Therefore, in the ongoing mass COVID-19 vaccination, the older adults are a growing public health concern. The authors provide an overview of the various types of COVID-19 vaccines approved for mass immunization of the population by the end of 2020, including older adults, as well as an overview of strategies and platforms to improve the effectiveness of vaccination of this population. In the final part, the authors propose for discussion a system for assessing the safety and monitoring the effectiveness of COVID-19 vaccines for the older adults.



    Food safety has been a substantial concern in agribusiness and the food industry, and serious food safety scares have eroded public confidence [1]. The mad cow disease scandal involving beef infected with bovine spongiform encephalopathy in the United Kingdom and the melamine contamination of baby formula in China, for example, has raised the interest of our well-informed global society in all matters pertaining to food safety [2,3]. Media reports have caused consumer panic and further contributed to the decline in public confidence [4]. Food safety is, therefore, an increasingly crucial issue not only for public health but also for countries' economic development and international reputation.

    Food safety refers to the prevention of illnesses resulting from the consumption of contaminated food [5] and is related to the hygiene standards of food that reach consumers [6]. It is a crucial element of consumer perceptions and decisions. Without seeing quality certifications, consumers may have difficulty evaluating product characteristics [7]. To reduce consumer uncertainty and safeguard public health, governments usually establish food safety laws or regulations or implement relevant policies [8]. Food safety certification labels are one such policy tool, which functions to differentiate a product from competitors by highlighting its attractiveness or guaranteeing consumers a certain level of quality [9]. Altmann [9] affirmed that certification labels can enhance product value and attractiveness and indicate to consumers a certain level of quality. Pancer et al. [10] contended that certification labels can increase product credibility. Brach et al. [11] stated that certification labels provide brand-like information cues that reduce the perceived risk of products.

    Food safety certification labels reduce consumers' screening efforts and information costs and simplify decision-making [12,13]. When food safety information is available, the average price that consumers are willing to pay for safe food increases [1]. However, in a previous study, we found that consumers do not easily recognize food safety certification labels and do not adequately understand them [14]. Regardless, the presence of these labels on food products can reduce consumer perceptions of risk [15], and consumers are willing to pay a premium price for such products [6,11,16]. Consumer willingness to pay (WTP) for food safety certification labels has been explored in investigations of the relationship between these labels and consumer attributes, including gender, age, income, and education [17,18]. Wang et al. [17] studied consumer WTP for labels on pork products and found that higher income and level of education were associated with higher WTP. Liu et al. [18] studied consumer WTP for eco-labeled rice and reported that WTP did not increase with consumer knowledge.

    In recent years, with the change of consumption habits, people buying bulk rice have turned to buy packaged rice. Packaged rice has become the primary rice product on the market for nuclear families in Taiwan. We investigated consumer cognition of and WTP for food safety certification labels on packaged rice. Because food safety, product quality, and certification labels have a nonmarket value, they cannot be evaluated directly through changes in market prices and manufacturer incomes. Thus, we used the contingent valuation method (CVM) to evaluate consumer WTP. In addition, based on the research cost, the limitation of the study only targeted major large cities in Taiwan as the subject of the questionnaire and did not extend to every city in Taiwan.

    However, the food safety certification mark is more complicated in Taiwan, which makes consumers unable to effectively face the diversified certification information to choose. This is an important problem faced by consumers when purchasing. As far as the industry is concerned, this study was based on the premise of food safety risks in different contexts to investigate consumer cognition of and WTP for food safety certification labels on packaged rice. If the design and presentation of a clear and uniform label can be used, it is bound to effectively enhance consumers' purchasing awareness and gain a deeper understanding of product characteristics. In addition, through the type of packaged rice, manufacturers can diversify product planning and highlight product characteristics. If consumers can effectively increase their awareness of food safety certification, it will indirectly affect the stability of the purchased products.

    The CVM, originally proposed by Ciriacy-Wantrup in 1947, is used for the valuation of nonmarket goods and services. Under this method, individual WTP for nonmarket goods is determined [19]. It has been widely applied for evaluating nonmarket goods, resources, and concepts, including ecological conservation, environmental resource protection, cultural asset preservation, landscapes, and food [20].

    The CVM entails building a hypothetical scenario to evaluate consumer WTP for typically invaluable goods through questionnaires. It assumes that consumer evaluation of prices of goods and services is rational and dependent on perception or preference. The CVM comprises the open- and closed-ended models; the closed-ended model can be further divided into a single-bounded model or a double-bounded model. Compared with the single-bounded dichotomous choice model, the double-bounded model is more efficient [19,21]. Respondents are assumed to have successively answered two questions (bids) about WTP. The amount presented in the second question depends on the respondents' response to the first bid (Ai). If they answer "yes" to the first WTP query, the second bid (Ayi) will be higher than the first bid (Ai<Ayi); if they answer "no, " the second bid will be lower than the first bid (Ani<Ai) [22]. Four responses are possible in the double-bounded model:

    Both answers are "yes" (pYY):

    pYY(Ai,Ayi)=Pr{AiMaxWTP and AyiMaxWTP}           =Pr{AiMaxWTP|AyiMaxWTP}Pr{AyiMaxWTP}           =Pr{AyiMaxWTP}=1Gc(Ayi) (1)

    Both answers are "no" (pNN):

    pNNnn(Ai,Ani)=Pr{Ai>MaxWTP and Ani>MaxWTP}=Pr{Ani>MaxWTP>0}          =Gc(Ani) (2)

    A "yes" followed by a "no" (pYN):

    pYN(Ai,Ayi)={AiMaxWTP<Ayi}=Gc(Ayi)Gc(Ai) (3)

    A "no" followed by a "yes" (pNY):

    pNY(Ai,Ani)={AniMaxWTP<Ai}=Gc(Ai)Gc(Ani) (4)

    In these four equations, pYY,pNN,pYN, and pNY represent the probabilities of each situation; MaxWTP represents the respondents' true maximum WTP, pYY represents the probability that respondents are willing to pay both the first and second bids, pNN represents the probability that respondents are unwilling to pay both the first and second bids, pYN represents the probability that respondents are willing to pay the first bid but are unwilling to pay the second bid, pNYrepresents the probability that respondents are unwilling to pay the first bid, but are willing to pay the second bid, and Gc(‧) represents the cumulative probability distribution.

    In Eqs. (3) and (4), the second bids are the upper and lower bounds, respectively, of the respondent's true maximum WTP. In Eqs. (1) and (2), the second bid represents the respondent's lower and upper WTP bounds, respectively. Given N respondents under the conditions of Ai,Ayi, and Ani, the log-likelihood function of the ith respondent is as follows:

    lnLD(θ)=Ni=1{dYYilnπYY(Ai,Ayi)+dNNilnπNN(Ai,Ani)+dYNilnπYN(Ai,Ayi)+dNY          lnπNY(Ai,Ani)} (5)

    where dYYi,dNNi,dYNi, and dNYi correspond to the probabilities of (1), (2), (3), and (4), respectively, for the respondent's WTP. Therefore, the maximum likelihood estimator for the double-bounded model (ˆθD) is the solution to the equation lnLD(ˆθD)θ=0. The asymptotic variance–covariance matrix for ˆθD is as follows:

    VD(ˆθD)=[E2lnLD(ˆθD)θθ]ID(ˆθD)1 (6)

    where ID(ˆθD)1 is an information matrix. The statistical efficiency of the double-bounded model is higher than that of the single-bounded model [19].

    Before distributing the formal questionnaire, we conducted a pretest, the primary purpose of which was to determine the respondents' WTP intervals, which served as a basis for the questionnaire. We asked the respondents, through an open-ended CVM, how much money they were willing to donate for a year under two circumstances. First, we imagined a food safety foundation responsible for supervising and participating in tracking and inspection. This foundation would have a trust for fundraising and would reduce the risk of food safety problems by ensuring the reliability of the inspection bodies. Second, the foundation would create a quick response (QR) code that, when scanned with a mobile QR code reader, would automatically direct consumers to product information and provide confirmation of the foundation's participation in the food safety inspection. The QR code would constitute a new tool for food safety certification. The WTP intervals are shown in Table 1.

    Table 1.  Pretest results: Frequency distribution of respondents' WTP.
    Amount of WTP(NT$/year/person) Number of people
    0 6
    100 4
    200* 1
    500* 3
    1,000 16
    1,200* 1
    2,000* 3
    3,000 2
    5,000 1
    10,000 3
    12,000 1
    total 41
    1 Result removed 10% of extreme values. * denotes an amount selected in the questionnaire.

     | Show Table
    DownLoad: CSV

    We introduced four price options [22]. The amounts in the pretest questionnaire were arranged from low to high, and 10% of the extreme values were removed. Hence, the amounts of 20%, 40%, 60%, and 80% were selected as the first bids. If the response to the first bid was "yes, " the amount of the first bid was increased by half that amount to serve as the second bid. Conversely, if the response to the first bid was "no, " the first bid was halved to serve as the second bid. The amounts are presented in Table 2.

    Table 2.  Initial WTP amounts.
    Group Amount of WTP (NT$*/year/person)
    A 200 (100/400)
    B 500 (250/1,000)
    C 1,200 (600/2400)
    D 2,000 (1,000/4,000)
    1 Only the second bid amounts are enclosed in parentheses. The second bid amount was determined from that of the first bid; if the first bid response was "no, " the first bid was reduced for the second bid (before the slash); if it was "yes, " the first bid amount was increased for the second bid (after the slash). * Unit prices were in New Taiwan Dollars (NT$), and the exchange rate was US$1 = NT$30.

     | Show Table
    DownLoad: CSV

    As Table 2 shows, in the formal questionnaire, the inquiry prices were designed to present one of four price options: A, B, C, and D. The questionnaires were randomly administered to the participants.

    Using the questionnaires, we conducted face-to-face interviews with primary food shoppers in Tainan City, Taiwan. To ensure the quality of the data collected and to explain the objectives of the survey, we recruited five trained investigators. The participants were willing to complete the survey under assurance of anonymity and confidentiality. All participants were approached at the entrances of traditional markets, supermarkets, and hypermarkets. After the investigators provided a brief introduction, the participants were asked whether they were the primary food shopper for their household. The questionnaires were distributed to 452 participants, of whom 28 refused further participation; therefore, the actual sample size was 434.

    As Table 3 shows, 30.9% of the participants were men and 69.1% were women, and 58.7% were aged between 40 and 59 years. Married and single participants comprised 67.7% and 32.3% of the total, respectively. In total, 66.8% of the participants had a monthly income of between NT$20,000 and NT$80,000. Three hundred twenty consumers (73.8%) expressed willingness to go to the supermarket to buy rice, and among respondents, rice expenditure was reported to account for less than 5% of total food expenditure (306 participants, 70.5%).

    Table 3.  Participants' demographic characteristics.
    Variable N % Variable N %
    Gender Male 134 30.9 Education level Junior high School 7 1.6
    Female 300 69.1 Senior high school 69 15.9
    Age < 20 5 1.2 College or university 252 58.1
    20–29 77 17.7 Graduate school 106 24.4
    30–39 74 17.1 Monthly income (NT$**) Below 20,000 23 5.3
    40–49 139 32.0 20,000–40,000 92 21.2
    50–59 116 26.7 40,000–60,000 125 28.8
    60 or over 23 5.3 60,000–80,000 73 16.8
    Marital status Married 140 32.3 80,000–100,000 60 13.8
    Single 294 67.7 Above 100,000 61 14.1
    Place of Purchase* Traditional market 47 10.8 Proportion of rice expenditure to total food expenditure Less than 5% 306 70.5
    Supermarket 320 73.8 6%–10% 100 23.0
    Rice merchant 53 12.2 11%–20% 18 4.2
    Other* 14 3.2 Over 21% 10 2.3
    Total 434 100
    Note: * Included farmers' alliance and organic and online shops. **Unit prices were in New Taiwan Dollars (NT$), and the exchange rate was US$1 = NT$30.

     | Show Table
    DownLoad: CSV

    Table 4 presents the results of the analysis of the participants' food safety cognition. In total, 50% of participants scored 5 points on certification cognition, which refers to awareness that a food safety certification is a standard of food safety assurance; 90% scored 3–5 points on health cognition, which refers to the need for health information about a product, which is associated with a positive evaluation of the product; and 47% scored 4 points on brand cognition, which is associated with trust of food manufacturers, businesses, and brands.

    Table 4.  Food safety cognition analysis.
    Variable (all scored from 1 to 5) Definition N %
    Certification cognition Awareness that food safety certification is a standard of food safety assurance. 1
    2
    3
    4
    5
    0
    0
    16
    170
    248
    0
    0
    3.69
    39.17
    57.14
    Health cognition Requirement for health information about a product, which is associated with a positive evaluation of the product. 1
    2
    3
    4
    5
    0
    7
    35
    227
    165
    0
    1.62
    8.06
    52.30
    38.02
    Brand cognition Food safety knowledge connected to trust of manufacturers, businesses, and brands. 1
    2
    3
    4
    5
    2
    23
    130
    204
    75
    0.46
    5.30
    29.95
    47.01
    17.28

     | Show Table
    DownLoad: CSV

    According to the pretest questionnaire results, base prices were set against which to evaluate respondents' WTP. Respondents were asked, "Would you be willing to pay if the foundation has a trust for fundraising to reduce the risk of food safety problems and ensure the reliability of inspection bodies and creates a QR code that, when scanned with a mobile QR code reader, directs consumers to product information and provides immediate confirmation of the foundation's participation in food safety inspection?" The price options were (in NT$) 200 (100/400), 500 (250/1,000), 1,200 (600/2,400), and 2,000 (1,000/4,000).

    After consideration of factors affecting WTP, this study focuses on variables such as socioeconomic background (income, gender, and education level), place of purchase(b1, b2, b3, b4), and food safety cognitive factors (certification cognition, health cognition, and brand cognition). In particular, this study did not include marital status variables in the model evaluation. The main reason is due to the decline in the marriage rate, the marriage status variable had an insignificant influence on the discussion of agricultural products [23,24]. Based on the theoretical model, an empirical model of the WTP for food safety certification was established, as represented by the following formula:

    lnWTP = f (Income, Gender, Edu, b1, b2, b3, b4, Certification cognition, Health cognition, Brand cognition).

    The WTP assessed in the present study represented hypothetical rather than actual WTP for food safety certification. The socioeconomic variables comprised ln(income)—a logarithm of the income of the respondent, gender, and education level. Place of purchase comprised b1, b2, and b3, dummy variables representing place of purchase (at supermarkets, traditional markets, and hypermarkets = 1, at other places = 0), and b4, a variable representing the proportion of rice expenditure to total food expenditure. From the empirical model, three Weibull distributions were generated for maximum likelihood estimation.

    The estimation results from the Weibull distributions are presented in Table 5 and described as follows. Significance was set at 5%. Gender was estimated to be positive and significant at 10% and 5% for women and men, respectively; the foregoing means that gender positively affected the amount of WTP, and women were more willing to pay than men. Place of purchase b1 and b3 were estimated to be positive and significant, indicating that buying packaged rice at supermarkets or hypermarkets had a positive effect on WTP, meaning that participants were willing to pay a higher amount for purchases of packaged rice at supermarkets or hypermarkets. Health cognition was estimated to be negative and significant, showing that health cognition negatively affected WTP, perhaps because participants did not sufficiently trust the foundation's assurance that the rice was safe. Scale values were set at 1% significance. The log-likelihood ratio was greater than 15.987, indicating that the model had high explanatory power.

    Table 5.  Estimation results of the evaluation function.
    Variables Coefficient Estimates (t-Values)
    Constant 9.73
    (6.47)***
    ln(Income) −0.19
    (1.53)
    Gender −0.36
    (2.36)**
    Education 0.07
    (0.71)
    b1 0.39
    (2.23)**
    b2 0.08
    (0.29)
    b3 0.4
    (1.97)**
    b4 0.12
    (1.13)
    Certification cognition 0.21
    (1.51)
    Health cognition −0.35
    (2.02)**
    Brand cognition −0.04
    (0.34)
    Scale 0.84
    (17.1)***
    Log likelihood −391.54
    Log-likelihood ratio 20.43**
    Note: *, **, *** were significant at 10%, 5%, and 1%, respectively. Log-likelihood ratio = (−2) × (restricted log-likelihood−log likelihood); χ2(10, 0.9) = 15.987.

     | Show Table
    DownLoad: CSV

    Table 6 shows the participants' WTP for food safety certification as estimated through the Weibull distribution. Per year per person, the mean mid-WTP was NT$1,311.07, the lower bound was NT$863.04, and the upper bound was NT$2,010.03.

    Table 6.  WTP for food safety certification.
    WTP Item Mean of Mid-WTP (NT$*/year/person) Lower Bound (NT$/year/person) Upper Bound (NT$/year/person)
    Food safety certification labels 1,311.07 863.04 2,010.03
    *Unit prices were in New Taiwan Dollars (NT$), and the exchange rate was US$1 = NT$30.

     | Show Table
    DownLoad: CSV

    In this study, we assessed consumer food safety cognition and WTP for food safety certification. After a questionnaire survey, the CVM was used to estimate the effect of personal variables on participants' WTP. To evaluate the WTP for food safety certification, income, gender, education level, buying behavior, and cognitive factors were used as model input variables. Being female, purchasing rice at supermarkets and hypermarkets, and health cognition resulted in higher WTP in the model, indicating that consumer trust in food safety certification can be rebuilt. Consumers are concerned with the health effects, place of origin, and brand, among other factors, of the food products they purchase. This information should be clearly presented on product packaging and advertisements for maximal accessibility.

    The description of the food safety certification is one of the important factors in establishing food safety, but the establishment of consumers' perception of food labeling is an important basis for food safety. This study shows that if consumers have correct health perceptions, the more they attach importance to food safety labels. The results of this study mainly found that Taiwan's food safety certification label is relatively complex, and consumers cannot effectively face the diverse certification information to choose. Therefore, as the Taiwan Agriculture Council has put forward the concept of production and sales history in recent years, it allows products to start from manufacturing, The integration of production, packaging, sales, and other places, combined with the simple and clear indication of the certification mark, will inevitably enhance the stability and awareness of consumers when choosing to buy. In addition, food safety education is another important result of this research. This research believes that if the certification mark can be simplified and clarified, it is bound to be introduced into the scope of school education so that students can understand the importance of food safety and certification during the learning process In the long term, the recognition of the mark will definitely effectively increase the awareness of food safety and certification marks, and indirectly will positively affect the clarity of the products to be purchased.

    Therefore, in the process of implementing food safety certification, the government should not only reduce the complexity of the labels but also establish a credible certification system so that consumers can easily recognize the labels. In addition, the foundation of food and agriculture education must be strengthened at the same time, and the understanding of food and the concept of health must be established. Only with the correct food and agriculture education can we effectively accumulate knowledge about food nutrition and indirectly be able to clearly distinguish the content of food safety certification. The food safety certification must not only allow consumers to improve the safety of the products they choose through food labels, but also in-depth basic education and learning, so that food safety label policies can effectively alleviate food safety problems.

    We would like to thank the constructive feedback provided by the reviewers.

    The authors declare no conflict of interest.

    This research was funded by Ministry of Science and Technology, Taiwan, R.O.C.: MOST 106-2410-H-309 -006 -MY2 and was funded by Business School of Yulin Normal University, China: MOST G2021SK02.


    Acknowledgments



    Thank you to the anonymous referees for providing useful comments and suggestions.

    Author contributions



    B.G.A.: idea and writing plan, approval of the final version, collection and analysis of literature, preparation of a draft manuscript; N.N.B.: concept, methodology, approval of the final review. All authors have read and agreed to the published version of the manuscript.

    Conflicts of interest



    The authors declare that they have no conflict of interests.

    [1] United Nations: Department of Economic and Social Affairs, Population Division (2019)  World Population Prospects 2019: Highlights (ST/ESA/SER.A/423) United Nations New York: Available from: https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf.
    [2] United Nations: Department of Economic and Social Affairs Population Dynamics World Population Prospects 2019 Available from: https://population.un.org/wpp/DataQuery/.
    [3] Bektas A, Schurman SH, Sen R, et al. (2017) Human T cell immunosenescence and inflammation in aging. J Leukoc Biol 102: 977-988. doi: 10.1189/jlb.3RI0716-335R
    [4] Austad SN, Hoffman JM (2018) Is antagonistic pleiotropy ubiquitous in aging biology? Evol Med Public Hlth 2018: 287-294. doi: 10.1093/emph/eoy033
    [5] Fülöp T, Larbi A, Witkowski JM (2019) Human Inflammaging. Gerontology 65: 495-504. doi: 10.1159/000497375
    [6] Pinti M, Appay V, Campisi J, et al. (2016) Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol 46: 2286-2301. doi: 10.1002/eji.201546178
    [7] Oh SJ, Lee JK, Shin OS (2019) Aging and the Immune System: The Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Netw 19: e37. doi: 10.4110/in.2019.19.e37
    [8] Crooke SN, Ovsyannikova IG, Poland GA, et al. (2019) Immunosenescence and human vaccine immune responses. Immun Ageing 16: 25. doi: 10.1186/s12979-019-0164-9
    [9] World Health Organization COVID-19 vaccines Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.
    [10] Center for Disease Control and Prevention Weekly Updates by Select Demographic and Geographic Characteristics Available from: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex.
    [11] Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096. doi: 10.1016/j.vaccine.2007.03.046
    [12] Gralinski LE, Menachery VD (2020) Return of the Coronavirus: 2019-nCoV. Viruses 12: 135. doi: 10.3390/v12020135
    [13] Cianci R, Franza L, Massaro MG, et al. (2020) The Interplay between Immunosenescence and Microbiota in the Efficacy of Vaccines. Vaccines (Basel) 8: 636. doi: 10.3390/vaccines8040636
    [14] Zhang Y, Zeng G, Pan H, et al. (2020) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis S1473–3099: 30987.
    [15] Xia S, Zhang Y, Wang Y, et al. (2020) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 21: 39-51. doi: 10.1016/S1473-3099(20)30831-8
    [16] Thompson HL, Smithey MJ, Surh CD, et al. (2020) Functional and Homeostatic Impact of Age-Related Changes in Lymph Node Stroma. Front Immunol 8: 706. doi: 10.3389/fimmu.2017.00706
    [17] Song CY, Xu J, He JQ, et al. (2020) Immune dysfunction following COVID-19, especially in severe patients. Sci Rep 10: 15838. doi: 10.1038/s41598-020-72718-9
    [18] Connors J, Bell MR, Marcy J, et al. (2021) The impact of immuno-aging on SARS-CoV-2 vaccine development. Geroscience 43: 31-51. doi: 10.1007/s11357-021-00323-3
    [19] Arvey A, Rowe M, Legutki JB, et al. (2020) Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immun Ageing 17: 28. doi: 10.1186/s12979-020-00193-x
    [20] Frawley T, van Gelderen F, Somanadhan S, et al. (2020) The impact of COVID-19 on health systems, mental health and the potential for nursing. Ir J Psychol Med 16: 1-7. doi: 10.1017/ipm.2020.105
    [21] Ponnappan S, Ponnappan U (2011) Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal 14: 1551-1585. doi: 10.1089/ars.2010.3228
    [22] Solana R, Pawelec G, Tarazona R (2006) Aging and innate immunity. Immunity 24: 491-494. doi: 10.1016/j.immuni.2006.05.003
    [23] Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15: 505-522. doi: 10.1038/s41569-018-0064-2
    [24] Gubbels Bupp MR, Potluri T, Fink AL, et al. (2018) The Confluence of Sex Hormones and Aging on Immunity. Front Immunol 9: 1269. doi: 10.3389/fimmu.2018.01269
    [25] van Eeden C, Khan L, Osman MS, et al. (2020) Natural Killer Cell Dysfunction and Its Role in COVID-19. Int J Mol Sci 21: 6351. doi: 10.3390/ijms21176351
    [26] Przemska-Kosicka A, Childs CE, Maidens C, et al. (2018) Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial. Front Immunol 9: 591. doi: 10.3389/fimmu.2018.00591
    [27] Guo H, Kumar P, Moran TM, et al. (2009) The functional impairment of natural killer cells during influenza virus infection. Immunol Cell Biol 87: 579-589. doi: 10.1038/icb.2009.60
    [28] Fulop T, Witkowski JM, Le Page A, et al. (2017) Intracellular signalling pathways: targets to reverse immunosenescence. Clin Exp Immunol 187: 35-43. doi: 10.1111/cei.12836
    [29] Zhou R, To KK, Wong YC, et al. (2020) Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 53: 864-877. doi: 10.1016/j.immuni.2020.07.026
    [30] Fulop T, Larbi A, Dupuis G, et al. (2018) Immunosenescence and Inflamm-Aging as Two Sides of the Same Coin: Friends or Foes? Front Immunol 8: 1960. doi: 10.3389/fimmu.2017.01960
    [31] Iberg CA, Jones A, Hawiger D (2017) Dendritic Cells As Inducers of Peripheral Tolerance. Trends Immunol 38: 793-804. doi: 10.1016/j.it.2017.07.007
    [32] Ray D, Yung R (2018) Immune senescence, epigenetics and autoimmunity. Clin Immunol 196: 59-63. doi: 10.1016/j.clim.2018.04.002
    [33] Agrawal A, Sridharan A, Prakash S, et al. (2012) Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol 8: 73-80. doi: 10.1586/eci.11.77
    [34] Agrawal A, Agrawal S, Gupta S (2017) Role of Dendritic Cells in Inflammation and Loss of Tolerance in the Elderly. Front Immunol 8: 896. doi: 10.3389/fimmu.2017.00896
    [35] Agrawal A, Agrawal S, Gupta S (2018) Role of Dendritic Cells in Aging. Handbook of Immunosenescence Cham: Springer.
    [36] Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181: 1036-1045. doi: 10.1016/j.cell.2020.04.026
    [37] Schröder AK, Rink L (2003) Neutrophil immunity of the elderly. Mech Ageing Dev 124: 419-425. doi: 10.1016/S0047-6374(03)00017-4
    [38] Butcher S, Chahel H, Lord JM (2000) Review article: ageing and the neutrophil: no appetite for killing? Immunology 100: 411-416. doi: 10.1046/j.1365-2567.2000.00079.x
    [39] Naccache PH, Lefebvre JS (2014) A straight neutrophil path to healthy aging? Blood 123: 154-156. doi: 10.1182/blood-2013-11-538256
    [40] Mócsai A (2013) Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 210: 1283-1299. doi: 10.1084/jem.20122220
    [41] Dinauer MC (2014) Disorders of neutrophil function: an overview. Methods Mol Biol 1124: 501-515. doi: 10.1007/978-1-62703-845-4_30
    [42] Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15: 505-522. doi: 10.1038/s41569-018-0064-2
    [43] Aiello A, Farzaneh F, Candore G, et al. (2019) Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol 10: 2247. doi: 10.3389/fimmu.2019.02247
    [44] Rubtsov AV, Rubtsova K, Fischer A, et al. (2011) Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood 118: 1305-1315. doi: 10.1182/blood-2011-01-331462
    [45] Bektas A, Schurman SH, Sen R, et al. (2017) Human T cell immunosenescence and inflammation in aging. J Leukoc Biol 102: 977-988. doi: 10.1189/jlb.3RI0716-335R
    [46] Tu W, Rao S (2016) Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection. Front Microbiol 7: 2111.
    [47] Gustafson CE, Kim C, Weyand CM, et al. (2020) Influence of immune aging on vaccine responses. J Allergy Clin Immunol 145: 1309-1321. doi: 10.1016/j.jaci.2020.03.017
    [48] Park S, Nahm MH (2011) Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 79: 314-320. doi: 10.1128/IAI.00768-10
    [49] Zhu FC, Guan XH, Li YH, et al. (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396: 479-488. doi: 10.1016/S0140-6736(20)31605-6
    [50] Schenkelberg T (2020) Vaccine-induced protection in aging adults and pandemic response. Biochem Biophys Res Commun S0006-291X(20)32020-9.
    [51] Ruan Q, Yang K, Wang W, et al. (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46: 846-848. doi: 10.1007/s00134-020-05991-x
    [52] McElhaney JE, Coler RN, Baldwin SL (2013) Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 12: 759-766. doi: 10.1586/14760584.2013.811193
    [53] Huff WX, Kwon JH, Henriquez M, et al. (2019) The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci 20: 2810. doi: 10.3390/ijms20112810
    [54] McElhaney JE, Verschoor CP, Andrew MK, et al. (2020) The immune response to influenza in older humans: beyond immune senescence. Immun Ageing 17: 10. doi: 10.1186/s12979-020-00181-1
    [55] Saletti G, Gerlach T, Jansen JM, et al. (2020) Older adults lack SARS CoV-2 cross-reactive T-lymphocytes directed to human coronaviruses OC43 and NL63. Sci Rep 10: 21447. doi: 10.1038/s41598-020-78506-9
    [56] Ma S, Wang C, Mao X, et al. (2019) B Cell Dysfunction Associated with Aging and Autoimmune Diseases. Front Immunol 10: 318. doi: 10.3389/fimmu.2019.00318
    [57] Cancro MP, Hao Y, Scholz JL, et al. (2009) B cells and aging: molecules and mechanisms. Trends Immunol 30: 313-318. doi: 10.1016/j.it.2009.04.005
    [58] Phalke S, Marrack P (2018) Age (autoimmunity) associated B cells (ABCs) and their relatives. Curr Opin Immunol 55: 75-80. doi: 10.1016/j.coi.2018.09.007
    [59] Bulati M, Caruso C, Colonna-Romano G (2017) From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by “inflamm-ageing”. Ageing Res Rev 36: 125-136. doi: 10.1016/j.arr.2017.04.001
    [60] Du SW, Arkatkar T, Jacobs HM, et al. (2019) Generation of functional murine CD11c+ age-associated B cells in the absence of B cell T-bet expression. Eur J Immunol 49: 170-178. doi: 10.1002/eji.201847641
    [61] Du SW, Arkatkar T, Al Qureshah F, et al. (2019) Functional Characterization of CD11c+ Age-Associated B Cells as Memory B Cells. J Immunol 203: 2817-2826. doi: 10.4049/jimmunol.1900404
    [62] Karnell JL, Kumar V, Wang J, et al. (2017) Role of CD11c+ T-bet+ B cells in human health and disease. Cell Immunol 321: 40-45. doi: 10.1016/j.cellimm.2017.05.008
    [63] Sachinidis A, Xanthopoulos K, Garyfallos A (2020) Age-Associated B Cells (ABCs) in the Prognosis, Diagnosis and Therapy of Systemic Lupus Erythematosus (SLE). Mediterr J Rheumatol 31: 311-318. doi: 10.31138/mjr.31.3.311
    [64] Hartley GE, Edwards ESJ, Aui PM, et al. (2020) Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol 5: eabf8891. doi: 10.1126/sciimmunol.abf8891
    [65] Cañete PF, Vinuesa CG (2020) COVID-19 Makes B Cells Forget, but T Cells Remember. Cell 183: 13-15. doi: 10.1016/j.cell.2020.09.013
    [66] Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, et al. (2020) B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Front Immunol 11: 611004. doi: 10.3389/fimmu.2020.611004
    [67] Hao Y, O'Neill P, Naradikian MS, et al. (2011) A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118: 1294-304. doi: 10.1182/blood-2011-01-330530
    [68] Park S, Nahm MH (2011) Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 79: 314-320. doi: 10.1128/IAI.00768-10
    [69] Smetana J, Chlibek R, Shaw J, et al. (2018) Influenza vaccination in the elderly. Hum Vaccin Immunother 14: 540-549. doi: 10.1080/21645515.2017.1343226
    [70] Kwong JC, Campitelli MA, Gubbay JB, et al. (2013) Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis 57: 820-827. doi: 10.1093/cid/cit404
    [71] Bonmarin I, Belchior E, Lévy-Bruhl D (2015) Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. Vaccine 33: 1099-1101. doi: 10.1016/j.vaccine.2015.01.023
    [72] Chiu C (2016) Seasonal influenza vaccines and hurdles to mutual protection. Clin Microbiol Infect 22: S113-S119. doi: 10.1016/j.cmi.2016.03.021
    [73] Koldaş ZL (2017) Yaşlı popülasyonda bağışıklama (aşılama) [Vaccination in the elderly population]. Turk Kardiyol Dern Ars 45: 124-127.
    [74] Derhovanessian E, Pawelec G (2012) Vaccination in the elderly. Microb Biotechnol 5: 226-232. doi: 10.1111/j.1751-7915.2011.00283.x
    [75] World Health Organization The COVID-19 candidate vaccine landscape and tracker Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
    [76] World Health Organization COVID-19 vaccines Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines?.
    [77] Precision vaccinations EpiVacCorona Vaccine Available from: https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine.
    [78] Novavax Coronavirus Vaccine Candidate Updates Available from: https://www.novavax.com/covid-19-coronavirus-vaccine-candidate-updates.
    [79] Keech C, Albert G, Cho I, et al. (2020) Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 383: 2320-2332. doi: 10.1056/NEJMoa2026920
    [80] Dai L, Gao GF (2020) Viral targets for vaccines against COVID-19. Nat Rev Immunol 18: 1-10.
    [81] Balakrishnan VS (2020) The arrival of Sputnik V. Lancet Infect Dis 20: 1128. doi: 10.1016/S1473-3099(20)30709-X
    [82] Sputnik V GENERAL INFORMATION Available from: https://sputnikvaccine.com/rus/about-vaccine/.
    [83] Johnson & Johnson Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate Available from: https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate.
    [84] Knoll MD, Wonodi C (2020) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet S0140-6736(20)32623-4.
    [85] Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
    [86] Centers for Disease Control and Prevention (CDC) Moderna COVID-19 Vaccine Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html.
    [87] BioRender COVID-19 Vaccine & Therapeutics Tracker Available from: https://biorender.com/covid-vaccine-tracker.
    [88] Coelingh K, Olajide IR, MacDonald P, et al. (2015) Efficacy and effectiveness of live attenuated influenza vaccine in school-age children. Expert Rev Vaccines 14: 1331-1346. doi: 10.1586/14760584.2015.1078732
    [89] Singanayagam A, Zambon M, Lalvani A, et al. (2018) Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect Dis 18: e25-e32. doi: 10.1016/S1473-3099(17)30360-2
    [90] Chua BY, Sekiya T, Jackson DC (2018) Opinion: Making Inactivated and Subunit-Based Vaccines Work. Viral Immunol 31: 150-158. doi: 10.1089/vim.2017.0146
    [91] Brickley EB, Wright PF (2017) Maximising the impact of inactivated polio vaccines. Lancet Infect Dis 17: 680-681. doi: 10.1016/S1473-3099(17)30236-0
    [92] Tripathi NK, Shrivastava A (2018) Recent Developments in Recombinant Protein-Based Dengue Vaccines. Front Immunol 9: 1919. doi: 10.3389/fimmu.2018.01919
    [93] de Vries RD, Rimmelzwaan GF (2016) Viral vector-based influenza vaccines. Hum Vaccin Immunother 12: 2881-2901. doi: 10.1080/21645515.2016.1210729
    [94] Logunov DY, Dolzhikova IV, Zubkova OV, et al. (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396: 887-897. doi: 10.1016/S0140-6736(20)31866-3
    [95] Humphreys IR, Sebastian S (2018) Novel viral vectors in infectious diseases. Immunology 153: 1-9. doi: 10.1111/imm.12829
    [96] Dalmo RA (2018) DNA vaccines for fish: Review and perspectives on correlates of protection. J Fish Dis 41: 1-9. doi: 10.1111/jfd.12727
    [97] Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
    [98] Lundstrom K (2020) Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol Sci 21: 5130. doi: 10.3390/ijms21145130
    [99] Dong Y, Dai T, Wei Y, et al. (2020) A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 5: 237. doi: 10.1038/s41392-020-00352-y
    [100] Armengaud J, Delaunay-Moisan A, Thuret JY, et al. (2020) The importance of naturally attenuated SARS-CoV-2 in the fight against COVID-19. Environ Microbiol 22: 1997-2000. doi: 10.1111/1462-2920.15039
    [101] Alsulaiman JW, Khasawneh AI, Kheirallah KA (2020) Could “trained immunity” be induced by live attenuated vaccines protect against COVID-19? Review of available evidence. J Infect Dev Ctries 14: 957-962. doi: 10.3855/jidc.12805
    [102] Fidel PL, Noverr MC (2020) Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? mBio 11: e00907-e00920.
    [103] Roukens AH, Soonawala D, Joosten SA, et al. (2011) Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 6: e27753. doi: 10.1371/journal.pone.0027753
    [104] Monath TP, Cetron MS, McCarthy K, et al. (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1: 207-214. doi: 10.4161/hv.1.5.2221
    [105] Al-Kassmy J, Pedersen J, Kobinger G (2020) Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses 12: 861. doi: 10.3390/v12080861
    [106] Locht C (2020) Vaccines against COVID-19. Anaesth Crit Care Pain Med 39: 703-705. doi: 10.1016/j.accpm.2020.10.006
    [107] Wagner A, Garner-Spitzer E, Jasinska J, et al. (2018) Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 8: 9825. doi: 10.1038/s41598-018-28111-8
    [108] Dugan HL, Henry C, Wilson PC (2020) Aging and influenza vaccine-induced immunity. Cell Immunol 348: 103998. doi: 10.1016/j.cellimm.2019.103998
    [109] van den Berg SPH, Wong A, Hendriks M, et al. (2018) Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults. Front Immunol 9: 82. doi: 10.3389/fimmu.2018.00082
    [110] Farina SF, Gao GP, Xiang ZQ, et al. (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613. doi: 10.1128/JVI.75.23.11603-11613.2001
    [111] Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10: 616-629. doi: 10.1016/j.ymthe.2004.07.013
    [112] Vogels R, Zuijdgeest D, van Rijnsoever R, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271. doi: 10.1128/JVI.77.15.8263-8271.2003
    [113] Nidetz NF, McGee MC, Tse LV, et al. (2020) Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther 207: 107453. doi: 10.1016/j.pharmthera.2019.107453
    [114] Hinz T, Kallen K, Britten CM, et al. (2017) The European Regulatory Environment of RNA-Based Vaccines. Methods Mol Biol 1499: 203-222. doi: 10.1007/978-1-4939-6481-9_13
    [115] Plotkin S (2014) History of vaccination. Proc Natl Acad Sci USA 111: 12283-12287. doi: 10.1073/pnas.1400472111
    [116] Dalmo RA (2018) DNA vaccines for fish: Review and perspectives on correlates of protection. J Fish Dis 41: 1-9. doi: 10.1111/jfd.12727
    [117] Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
    [118] Lundstrom K (2020) Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol 21: 5130. doi: 10.3390/ijms21145130
    [119] Broderick KE, Humeau LM (2017) Enhanced Delivery of DNA or RNA Vaccines by Electroporation. Methods Mol Biol 1499: 193-200. doi: 10.1007/978-1-4939-6481-9_12
    [120] Zheng Z, Diaz-Arévalo D, Guan H, et al. (2018) Noninvasive vaccination against infectious diseases. Hum Vaccin Immunother 14: 1717-1733. doi: 10.1080/21645515.2018.1461296
    [121] Moderna Moderna's Company History Available from: https://www.modernatx.com/about-us/moderna-facts.
    [122] Soiza RL, Scicluna C, Thomson EC (2021) Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 50: 279-283. doi: 10.1093/ageing/afaa274
    [123] Di Pasquale A, Preiss S, Tavares Da Silva F, et al. (2015) Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel) 3: 320-343. doi: 10.3390/vaccines3020320
    [124] Zepp F (2010) Principles of vaccine design-Lessons from nature. Vaccine 28: C14-C24. doi: 10.1016/j.vaccine.2010.07.020
    [125] Levin Y, Kochba E, Shukarev G, et al. (2016) A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34: 5262-5272. doi: 10.1016/j.vaccine.2016.09.008
    [126] Del Giudice G, Rappuoli R, Didierlaurent AM (2018) Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol 39: 14-21. doi: 10.1016/j.smim.2018.05.001
    [127] Mascola JR, Fauci AS (2020) Novel vaccine technologies for the 21st century. Nat Rev Immunol 20: 87-88. doi: 10.1038/s41577-019-0243-3
    [128] Tregoning JS, Russell RF, Kinnear E (2018) Adjuvanted influenza vaccines. Hum Vaccin Immunother 14: 550-564. doi: 10.1080/21645515.2017.1415684
    [129] Trucchi C, Paganino C, Orsi A, et al. (2015) Influenza vaccination in the elderly: why are the overall benefits still hotly debated? J Prev Med Hyg 56: E37-E43.
    [130] Bonmarin I, Belchior E, Lévy-Bruhl D (2015) Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. Vaccine 33: 1099-1101. doi: 10.1016/j.vaccine.2015.01.023
    [131] Koldaş ZL (2017) Vaccination in the elderly population. Turk Kardiyol Dern Ars 45: 124-127.
    [132] Rizzo C, Rezza G, Ricciardi W (2018) Strategies in recommending influenza vaccination in Europe and US. Hum Vaccin Immunother 14: 693-698. doi: 10.1080/21645515.2017.1367463
    [133] Triglav TK, Poljak M (2013) Vaccination indications and limits in the elderly. Acta Dermatovenerol Alp Pannonica Adriat 22: 65-70.
    [134] Cano Gutierrez C, Reyes-Ortiz C, Borda MG, et al. (2016) Self-reported vaccination in the elderly: SABE Bogota study, Colombia. Colomb Med (Cali) 47: 25-30. doi: 10.25100/cm.v47i1.2107
    [135] Zeevat F, van der Schans J, Boersma WG, et al. (2019) Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine 37: 6282-6284. doi: 10.1016/j.vaccine.2019.08.051
    [136] Naito T, Yokokawa H, Watanabe A (2018) Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan. J Infect Chemother 24: 496-498. doi: 10.1016/j.jiac.2018.01.004
    [137] Domínguez A, Soldevila N, Toledo D, et al. (2016) Project Pi12/02079 Working Group. Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study. Hum Vaccin Immunother 12: 1891-1899.
    [138] Francisco PM, Borim FS, Neri AL (2015) Vaccination against influenza in the elderly: data from FIBRA, Campinas, São Paulo, Brazil. Cien Saude Colet 20: 3775-3786. doi: 10.1590/1413-812320152012.19702014
    [139] Forstner C, Kwetkat A, Schleenvoigt B, et al. (2018) Risikoimpfungen im Alter [Vaccinations in the elderly - who, when and which vaccine to use]. MMW Fortschr Med 160: 52-61. doi: 10.1007/s15006-018-0029-8
    [140] Norton EB (2019) Altered responses to pneumococcal vaccination in an elderly diabetic Japanese vaccine trial: The risk of concurrent vaccination strategies. J Diabetes Complications 33: 189-190. doi: 10.1016/j.jdiacomp.2018.12.007
    [141] Kajikawa N, Kataoka Y, Goto R, et al. (2019) Factors associated with influenza vaccination in Japanese elderly outpatients. Infect Dis Health 24: 212-221. doi: 10.1016/j.idh.2019.07.002
    [142] de Boer PT, Pouwels KB, Cox JM, et al. (2013) Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 31: 1276-1283. doi: 10.1016/j.vaccine.2012.12.067
    [143] Paccalin M, Weinberger B, Nicolas JF, et al. (2010) The intradermal vaccination route—an attractive opportunity for influenza vaccination in the elderly. Eur Geriatr Med 1: 82-87. doi: 10.1016/j.eurger.2010.03.004
    [144] Wang J, Peng Y, Xu H, et al. (2020) The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 21: 225. doi: 10.1208/s12249-020-01744-7
    [145] Escobar LE, Molina-Cruz A, Barillas-Mury C (2020) BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA 117: 17720-17726. doi: 10.1073/pnas.2008410117
    [146] Kim YC, Park JH, Prausnitz MR (2012) Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64: 1547-1568. doi: 10.1016/j.addr.2012.04.005
    [147] Zhang L, Wang W, Wang S (2015) Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 14: 1509-1523. doi: 10.1586/14760584.2015.1081067
    [148] Forster AH, Witham K, Depelsenaire ACI, et al. (2020) Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS Med 17: e1003024. doi: 10.1371/journal.pmed.1003024
    [149] Rouphael NG, Paine M, Mosley R, et al. (2017) TIV-MNP 2015 Study Group. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 390: 649-658. doi: 10.1016/S0140-6736(17)30575-5
    [150] Korkmaz E, Balmert SC, Sumpter TL, et al. (2021) Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev 171: 164-186. doi: 10.1016/j.addr.2021.01.022
    [151] Nguyen TT, Oh Y, Kim Y, et al. (2021) Progress in microneedle array patch (MAP) for vaccine delivery. Hum Vaccin Immunother 17: 316-327. doi: 10.1080/21645515.2020.1767997
    [152] Hossain MK, Ahmed T, Bhusal P, et al. (2020) Microneedle Systems for Vaccine Delivery: the story so far. Expert Rev Vaccines 19: 1153-1166. doi: 10.1080/14760584.2020.1874928
    [153] Weinberger B (2020) Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscip Top Gerontol Geriatr. Basel Karger 43: VI-IX.
    [154] Costa R, Castagna A, Ruotolo G (2021) COVID-19 and cardiovascular problems in elderly patients: Food for thought. Aging Med (Milton) 28: 10.1002/agm2.12149.
    [155] Napoli C, Tritto I, Benincasa G, et al. (2020) Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. Ann Med Surg (Lond) 57: 236-243. doi: 10.1016/j.amsu.2020.07.054
    [156] O'Neill LAJ, Netea MG (2020) BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 20: 335-337. doi: 10.1038/s41577-020-0337-y
    [157] European Commission I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly Available from: https://cordis.europa.eu/project/id/634446.
    [158] European Centre for Disease Prevention and Control Generic protocol on enhanced surveillance for invasive pneumococcal disease at the EU/EEA level. Stockholm: ECDC Available from: https://www.ecdc.europa.eu/sites/default/files/documents/SpIDnet_Protocol_enhanced_surveillance-2018.pdf.
    [159] Dirmesropian S, Wood JG, MacIntyre CR, et al. (2016) Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. Pharmacoeconomics 34: 723-731. doi: 10.1007/s40273-016-0393-0
    [160] Gilbert SC (2012) T-cell-inducing vaccines—what's the future. Immunology 135: 19-26. doi: 10.1111/j.1365-2567.2011.03517.x
    [161] Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. (2021) T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 27: 270-278. doi: 10.1038/s41591-020-01194-5
    [162] van Marum RJ (2020) Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol 86: 2014-2016. doi: 10.1111/bcp.14539
  • This article has been cited by:

    1. Ayako Ebata, Mauricio Espinoza, Giel Ton, Food safety certification in urban food markets: the willingness to pay for safer meat in Peru, 2025, 1876-4517, 10.1007/s12571-024-01512-6
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6146) PDF downloads(330) Cited by(14)

Figures and Tables

Figures(2)  /  Tables(3)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog